Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Major discovery provides new hope for blood cancer patients

Written by | 13 May 2022

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within… read more.

Patient possibly cured of HIV infection by special stem-cell transplant

Written by | 23 Feb 2022

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping… read more.

European Commission approval for Venclyxto + a hypomethylating agent for newly diagnosed acute myeloid leukemia – AbbVie

Written by | 3 Jun 2021

AbbVie announced that the European Commission (EC) has approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly… read more.

EU CHMP recommends approval of Onureg for acute myeloid leukemia – Bristol Myers Squibb

Written by | 30 Apr 2021

Bristol Myers Squibb has announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Onureg (azacitidine tablets; CC-486) as a… read more.

FDA approval of additional indication for Vyxeos for the treatment of secondary acute myeloid leukemia in pediatric patients – Jazz Pharma

Written by | 13 Apr 2021

Jazz Pharmaceuticals plc has announced that the FDA approved a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.